Shots:
- Alvotech will lead the development, registration, and supply of the biosimilars, while Teva will be exclusively commercializing the products in the US. Alvotech will receive upfront with subsequent milestone payments over the next several years
- The companies will share the profit from the commercialization of the biosimilars. The collaboration leverages Teva’s commercial presence and extensive infrastructure in the US along with Alvotech’s experience and state-of-the-art biologics manufacturing
- The collaboration will improve patient access for high-quality biosimilar medicines in the US
Click here to read full press release/ article | Ref: Teva | Image: PharmaShots
